Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ (brexanolone) injection CIV, the first treatment specifically indicated for postpartum depression, commercially launched in the U.S. in late-June, with first patients treated in July 2019 Commercial execution is progressing as expected and on-track across key focus areas including
View HTML
Toggle Summary Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on August 1, 2019 , the
View HTML
Toggle Summary Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast”
Data from Phase 2 open-label study of SAGE-217 in bipolar depression demonstrate rapid improvement compared to baseline; analysis of datasets from previously completed studies reveal encouraging findings relevant to the development of SAGE-217 in treatment-resistant depression and generalized
View HTML
Toggle Summary Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019 , the Compensation Committee of Sage’s Board of
View HTML
Toggle Summary Sage Therapeutics to Host “Sage FutureCast” Webcast
Event will provide an R&D and portfolio review across the depression, neurology and neuropsychiatric franchises CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system
View HTML
Toggle Summary Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare
View HTML
Toggle Summary Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
On track for full commercial launch in the U.S. in late June CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 14, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019 , the Compensation Committee of Sage’s Board of
View HTML